Riverbridge Partners LLC Sells 30,070 Shares of Repligen Corporation $RGEN

Riverbridge Partners LLC reduced its position in Repligen Corporation (NASDAQ:RGEN) by 8.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 313,365 shares of the biotechnology company’s stock after selling 30,070 shares during the period. Riverbridge Partners LLC owned approximately 0.56% of Repligen worth $51,348,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. XTX Topco Ltd raised its holdings in shares of Repligen by 34.1% in the 2nd quarter. XTX Topco Ltd now owns 17,352 shares of the biotechnology company’s stock worth $2,158,000 after acquiring an additional 4,417 shares during the last quarter. Iron Triangle Partners LP acquired a new position in Repligen during the 3rd quarter valued at about $36,091,000. Delta Investment Management LLC bought a new stake in Repligen during the 3rd quarter worth approximately $6,779,000. Congress Asset Management Co. raised its stake in shares of Repligen by 43.4% in the third quarter. Congress Asset Management Co. now owns 218,592 shares of the biotechnology company’s stock worth $29,219,000 after purchasing an additional 66,142 shares during the last quarter. Finally, Cinctive Capital Management LP bought a new position in shares of Repligen in the third quarter valued at approximately $3,398,000. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 0.1%

RGEN stock opened at $114.42 on Friday. The stock has a market cap of $6.45 billion, a P/E ratio of 134.61, a P/E/G ratio of 2.23 and a beta of 1.14. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. The stock’s fifty day simple moving average is $136.26 and its two-hundred day simple moving average is $146.37. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $175.77.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $197.91 million during the quarter, compared to analyst estimates of $192.23 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The business’s revenue was up 18.1% compared to the same quarter last year. During the same period last year, the firm posted $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Analysts expect that Repligen Corporation will post 1.72 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on RGEN. UBS Group decreased their price target on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Wells Fargo & Company dropped their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. HC Wainwright upped their target price on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, KeyCorp reissued an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $176.92.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.